sunvozertinib   Click here for help

GtoPdb Ligand ID: 11672

Synonyms: DZD-9008 | DZD9008 | Example 52 [WO2019149164A1]
Approved drug
sunvozertinib is an approved drug (China (2023))
Compound class: Synthetic organic
Comment: We obtained the chemical structure for sunvozertinib from WHO Proposed list 125, in which it is described as a tyrosine kinase inhibitor with proposed antineoplastic action. This mapped to PubChem CID 139377809. Sunvozertinib is one of the compounds that are claimed in Dizal (Jiangsu) Pharmaceutical's patent WO2019149164A1 as ERBB/BTK inhibitors [2]. Subsequent information revealed sunvozertinib (DZD9008) as an oral, irreversible inhibitor with selectivity for mutant EGFR [3].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 4
Rotatable bonds 11
Topological polar surface area 114.88
Molecular weight 583.25
XLogP 4.47
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C=CC(=O)Nc1cc(Nc2nccc(n2)Nc2cc(Cl)c(cc2C(O)(C)C)F)c(cc1N1CC[C@H](C1)N(C)C)OC
Isomeric SMILES Clc1c(cc(c(Nc2nc(ncc2)Nc2c(cc(c(c2)NC(=O)C=C)N2C[C@@H](CC2)N(C)C)OC)c1)C(C)(C)O)F
InChI InChI=1S/C29H35ClFN7O3/c1-7-27(39)34-22-14-23(25(41-6)15-24(22)38-11-9-17(16-38)37(4)5)35-28-32-10-8-26(36-28)33-21-13-19(30)20(31)12-18(21)29(2,3)40/h7-8,10,12-15,17,40H,1,9,11,16H2,2-6H3,(H,34,39)(H2,32,33,35,36)/t17-/m1/s1
InChI Key BTMKEDDEMKKSEF-QGZVFWFLSA-N
No information available.
Summary of Clinical Use Click here for help
Sunvozertinib was advanced as a clinical candidate for tumours bearing EGFR mutations (e.g. the resistance variant exon20ins) [3]. First international approval was granted in China in August 2023 [1], for locally advanced or metastatic NSCLC with EGFR exon20ins mutations.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05712902 DZD9008 in Pretreated Lung Cancer Patients With EGFR Exon20 Insertion Mutation Phase 2 Interventional Dizal Pharmaceuticals